Auven Therapeutics, Icahn School of Medicine at Mount Sinai deal

Mount Sinai granted private equity firm Auven Therapeutics (formerly Celtic Therapeutics) exclusive, worldwide rights to develop and commercialize Kiacta eprodisate to treat chronic sarcoidosis. Auven

Read the full 259 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE